Key Drivers
- Strong Liquidity
- Weak Core Profitability
- Mixed Earnings Quality
AIAI Summary
TBPH has shifted from a pipeline-driven biotech to a cash-rich restructuring/optional value story, so the investment case now hinges on disciplined capital allocation, successful cost cuts, and YUPELRI monetization rather than clinical upside, with execution and strategic-review uncertainty as the main risks.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Weak Core Profitability
- •Mixed Earnings Quality
TBPH has a very strong, low-debt balance sheet and cheap-looking earnings multiple, but recent results show weak core profitability and mixed earnings quality.
Price Behavior
Key Price Behavior Insights:
- •Dip Buying
- •Failed Rebound
- •Weak Momentum
TBPH drifted modestly lower over the last month, with repeated dip-buying near $16.3-$16.5 but a failed rebound back under $17 that leaves the short-term chart weak.
Bounce to $17.02/$17.01 failed, then price slipped back under support on
Sentiment & News
Key News Insights:
- •Earnings beat
- •Cost reduction
- •Legal scrutiny
Theravance Biopharma beat Q1 expectations with higher YUPELRI revenue, lower costs, and a strong cash/no-debt balance sheet, but investor investigations and a pipeline setback keep the outlook mixed.
The news is modestly positive for fundamentals and valuation support, but near-term sentiment may stay capped by litigation risk and pipeline uncertainty
Similar Companies in Healthcare
Other companies in the same sector with AI ratings